Moderna (MRNA) Issues Update on Investigational RSV Vaccine
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/10/2026
- Wall St set for subdued open as markets monitor Hormuz situation
- JPMorgan lifts S&P 500 target to 8,000 on strong earnings
- Jefferies cuts Apple rating as higher-priced iPhone roadmap looks difficult
- Oil rises nearly 2% as Iran tempers hopes of Hormuz reopening
- Intel stock stumbles following blockbuster $15 billion equity offering
- After-Hours Movers: TEAM, NET, TWLO, DOCS, FROG, DV, TTD, ABNB, DKNG, SG, RKT
- After-Hours Stock Movers: WDC, SNDK, FIG, APP, HUBS, SOUN, DASH, XYZ, Z, FLNC
- After-Hours Movers: SPCX, AMD, ANET, PINS, APPS, UPST, ZETA, BKNG, LCID, CPNG, MTCH
- After-Hours Stock Movers: PLTR, SNAP, ON, ICHR, WGS, WHR
- After-Hours Stock Movers: AAPL, AMZN, COIN, RBLX, RDDT, AXTI, FND, WU, GDDY
Moderna Announces Update on Investigational RSV Vaccine
May 10, 2024 7:03 AM EDTU.S. FDA has informed Moderna that due to administrative constraints, the agency will not complete its review of mRNA-1345 by the PDUFA date of May 12, 2024
Agency has indicated it expects to complete the review by end of May
CAMBRIDGE, MA / ACCESSWIRE / May 10, 2024 / Moderna, Inc. (NASDAQ: MRNA) today announced it has been notified by the U.S. Food and Drug Administration (FDA) that due to administrative constraints, the agency does not expect to complete its review of the Biologics License Application (BLA) for... More
